143 related articles for article (PubMed ID: 21560524)
21. The use of adjusted preoperative CA 19-9 to predict the recurrence of resectable pancreatic cancer.
Kang CM; Kim JY; Choi GH; Kim KS; Choi JS; Lee WJ; Kim BR
J Surg Res; 2007 Jun; 140(1):31-5. PubMed ID: 17418869
[TBL] [Abstract][Full Text] [Related]
22. Prognostic impact of perioperative serum CA 19-9 levels in patients with resectable pancreatic cancer.
Kondo N; Murakami Y; Uemura K; Hayashidani Y; Sudo T; Hashimoto Y; Nakashima A; Sakabe R; Shigemoto N; Kato Y; Ohge H; Sueda T
Ann Surg Oncol; 2010 Sep; 17(9):2321-9. PubMed ID: 20336387
[TBL] [Abstract][Full Text] [Related]
23. Multivariate analysis of the prognostic value of CEA and CA 19-9 serum levels in colorectal cancer.
Reiter W; Stieber P; Reuter C; Nagel D; Lau-Werner U; Lamerz R
Anticancer Res; 2000; 20(6D):5195-8. PubMed ID: 11326694
[TBL] [Abstract][Full Text] [Related]
24. Clinical significance of CEA and CA19-9 in postoperative follow-up of colorectal cancer.
Yakabe T; Nakafusa Y; Sumi K; Miyoshi A; Kitajima Y; Sato S; Noshiro H; Miyazaki K
Ann Surg Oncol; 2010 Sep; 17(9):2349-56. PubMed ID: 20217258
[TBL] [Abstract][Full Text] [Related]
25. CEA and CA 19-9 as prognostic indexes in colorectal cancer.
Forones NM; Tanaka M
Hepatogastroenterology; 1999; 46(26):905-8. PubMed ID: 10370636
[TBL] [Abstract][Full Text] [Related]
26. Comparison of serum CA72-4, CEA, TPA, CA19-9 and CA125 levels in gastric cancer patients and correlation with recurrence.
Lai IR; Lee WJ; Huang MT; Lin HH
Hepatogastroenterology; 2002; 49(46):1157-60. PubMed ID: 12143226
[TBL] [Abstract][Full Text] [Related]
27. The diagnostic importance of CEA and CA 19-9 for the early diagnosis of pancreatic carcinoma.
Nazli O; Bozdag AD; Tansug T; Kir R; Kaymak E
Hepatogastroenterology; 2000; 47(36):1750-2. PubMed ID: 11149048
[TBL] [Abstract][Full Text] [Related]
28. [Antigens (CEA and CA 19-9) in diagnosis and prognosis colorectal cancer].
Grotowski M
Pol Merkur Lekarski; 2002 Jan; 12(67):77-80. PubMed ID: 11957811
[TBL] [Abstract][Full Text] [Related]
29. CA 242 in comparison with established tumour markers in colorectal, pancreatic and lung cancer.
Hasholzner U; Stieber P; Reiter W; Zimmermann A; Hofmann K; Schalhorn A
Anticancer Res; 1999; 19(4A):2477-80. PubMed ID: 10470177
[TBL] [Abstract][Full Text] [Related]
30. Increase in both CEA and CA19-9 in sera is an independent prognostic indicator in colorectal carcinoma.
Nozoe T; Rikimaru T; Mori E; Okuyama T; Takahashi I
J Surg Oncol; 2006 Aug; 94(2):132-7. PubMed ID: 16847905
[TBL] [Abstract][Full Text] [Related]
31. Is it reasonable to add preoperative serum level of CEA and CA19-9 to staging for colorectal cancer?
Chen CC; Yang SH; Lin JK; Lin TC; Chen WS; Jiang JK; Wang HS; Chang SC
J Surg Res; 2005 Apr; 124(2):169-74. PubMed ID: 15820244
[TBL] [Abstract][Full Text] [Related]
32. [The prognostic value of CA 19-9 in the preoperative work-up of pancreatic cancer patients].
Grinbaum R; Nissan A; Beglaibter N; Cohen T; Peretz T; Freund HR
Harefuah; 2006 Nov; 145(11):793-4, 863. PubMed ID: 17183947
[TBL] [Abstract][Full Text] [Related]
33. Undetectable preoperative levels of serum CA 19-9 correlate with improved survival for patients with resectable pancreatic adenocarcinoma.
Berger AC; Meszoely IM; Ross EA; Watson JC; Hoffman JP
Ann Surg Oncol; 2004 Jul; 11(7):644-9. PubMed ID: 15197014
[TBL] [Abstract][Full Text] [Related]
34. Prognostic value of preoperative serum levels of CEA, CA 19-9 and CA 72-4 in gastric carcinoma.
Reiter W; Stieber P; Reuter C; Nagel D; Cramer C; Pahl H; Fateh-Moghadam A
Anticancer Res; 1997; 17(4B):2903-6. PubMed ID: 9329559
[TBL] [Abstract][Full Text] [Related]
35. Increased levels of both carbohydrate antigen 19-9 and duke pancreatic monoclonal antigen type 2 reflect postoperative prognosis in patients with pancreatic carcinoma.
Shibata K; Iwaki K; Kai S; Ohta M; Kitano S
Pancreas; 2009 Aug; 38(6):619-24. PubMed ID: 19436235
[TBL] [Abstract][Full Text] [Related]
36. The effect on prognosis of postoperative CA 19-9 level in patients with pancreatic cancer.
Kilickap S; Arslan C
Am J Clin Oncol; 2010 Jun; 33(3):320; author reply 320. PubMed ID: 20526087
[No Abstract] [Full Text] [Related]
37. Can preoperative CA19-9 and CEA levels predict the resectability of patients with pancreatic adenocarcinoma?
Kim YC; Kim HJ; Park JH; Park DI; Cho YK; Sohn CI; Jeon WK; Kim BI; Shin JH
J Gastroenterol Hepatol; 2009 Dec; 24(12):1869-75. PubMed ID: 19686409
[TBL] [Abstract][Full Text] [Related]
38. The use of serologic tumor markers in gastrointestinal malignancies.
Posner MR; Mayer RJ
Hematol Oncol Clin North Am; 1994 Jun; 8(3):533-53. PubMed ID: 8707771
[TBL] [Abstract][Full Text] [Related]
39. Serum CA 242 in pancreatic cancer. Comparison with CA 19-9 and CEA.
Pezzilli R; Billi P; Plate L; Laudadio MA; Sprovieri G
Ital J Gastroenterol; 1995; 27(6):296-9. PubMed ID: 8562994
[TBL] [Abstract][Full Text] [Related]
40. CEA, TPS, CA 19-9 and CA 72-4 and the fecal occult blood test in the preoperative diagnosis and follow-up after resective surgery of colorectal cancer.
Griesenberg D; Nürnberg R; Bahlo M; Klapdor R
Anticancer Res; 1999; 19(4A):2443-50. PubMed ID: 10470173
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]